Ligand Pharmaceuticals IncorporatedLGNDNASDAQ
Loading
Operating Income ContractionContracting
Percentile Rank71
3Y CAGR+149.6%
5Y CAGR+4.7%
Year-over-Year Change
Profit from core business operations before interest and taxes
3Y CAGR
+149.6%/yr
vs -63.1%/yr prior
5Y CAGR
+4.7%/yr
Recent acceleration
Acceleration
+212.6pp
Accelerating
Percentile
P71
Within normal range
vs 5Y Ago
1.3x
Solid growth
Streak
1 yr
Consecutive growthContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $47.20M | +308.8% |
| 2024 | $-22.61M | -289.3% |
| 2023 | $11.94M | +293.2% |
| 2022 | $3.04M | -97.1% |
| 2021 | $103.85M | +176.9% |
| 2020 | $37.50M | -95.4% |
| 2019 | $807.08M | +392.9% |
| 2018 | $163.73M | +140.5% |
| 2017 | $68.08M | +55.1% |
| 2016 | $43.88M | - |